Ketamine one has partnered with a virtual reality company to begin its scent-based VR therapy platform.
KetamineOne Capital Limited (NEO: MEDI), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce it has signed an exclusive agreement for the use of virtual reality (“VR”) technology in psychedelic treatments with OVR Tech LLC (“OVR Technology”) to provide its INHALE Wellness Platform over an initial term of two years in Ketamine One’s clinics. The INHALE Wellness Platform is an olfactory-enabled VR platform designed to deepen immersion, promote relaxation and help manage stress.
Pursuant to the terms and conditions of the exclusive agreement, OVR Technology will provide its proprietary technology and services for Ketamine One to use with its psychedelic-assisted treatments involving ketamine, psilocybin, DMT and MDMA in order to help improve patient outcomes. OVR Technology’s INHALE Wellness Platform combines the benefits of mindfulness, breathwork and meditation with the next generation of aromatherapy. It includes a head-mounted display, the ION device (the “ION”) and scent cartridges, as well as several scent-focused nature scenes. The ION is lightweight, wireless and emits scent particles in coordination with VR technology designed to deepen a patient’s immersive experience.
The Architecture of Scent® platform and ION Device
OVR Technology’s Architecture of Scent® platform brings together software, Scentware™, and hardware via the ION, while also including replaceable cartridges and an Olfactory Experience Engine that allows scent to be triggered during a VR experience. Scents delivered through the ION are water-based and made from a combination of natural and synthetic ingredients that have undergone extensive testing. While VR technology is widely known to incorporate sight and sound, this partnership provides Ketamine One with the capability to generate more realistic Immersive Virtual Reality (“IVR”) service offerings via scent at its network of clinics, which is expected to enhance experiences and help improve patient treatment outcomes.
The concept for the Architecture of Scent® and ION device was based on the idea that scent in VR could dramatically increase immersion. Computer simulations in which patients can interact within virtual three-dimensional environments can help put patients in calming settings and improve relaxation through the addition of scents. Research has shown that scents elicit emotional and evocative associations and can immediately alter mood.1 Other research shows that, as soon as an odor is registered by the brain, it activates the amygdala-hippocampal complex in the limbic system where emotions, memories, and associations are processed, nearly instantaneously.
About OVR Technology
Founded in 2017, OVR Technology is based in Burlington, Vermont and is a leader in providing scent solutions for virtual reality, augmented reality and other digital environments. OVR Technology combines people’s most primal sense, which is smell, with today’s most advanced technology, to unlock the potential of virtual reality. Better virtual reality, better reality. Learn more at https://ovrtechnology.com.
About Ketamine One
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.